Huntington Disease Clinical Trial
Official title:
Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria
Huntington's disease is a hereditary disease of rare autosomal dominant transmission, both
neurodegenerative and neuro-psychiatric. Clinically, there are motor symptoms (chorea),
cognitive disorders (dementia) and psychiatric disorders.
Among motor disorders, dysarthria is a commonly found symptom. This is classically referred
to as hyperkinetic dysarthria according to the criteria of Darley's classification. However,
this old classification (1969) is only based on perceptual analysis and lack of specificity.
Moreover, in the course of the disease, chorea (control of the striatal attack D2) decreases
to give place to a parkinsonian syndrome (control of the striatal attack D1) and the
dysarthria also evolves towards a hypokinetic form . It also seems likely that cerebellar
involvement (responsible for ataxia) contributes to dysarthria.
No studies have been published to date to characterize dysarthria in Huntington's disease in
a quantified, objective and specific manner. However, Canan Ozsancak describes choreic
dysarthria as heterogeneous according to the patients and variable according to the
productions. A perceptual study reports an imprecision of the consonants, a lengthening of
the pauses, a variable flow, an absence of modulation of the pitch and a hoarse voice.
Finally, few patients are cared for in speech therapy and there is no specific
rehabilitation strategy: this would require - and justify a more precise study of the
dysarthria of these patients.
The Clinical Evaluation of Dysarthria developed by Pascal Auzou and Véronique
Rolland-Monnoury is a recent and partially standardized tool, combining qualitative and
quantitative evaluation, which seems adapted to try to better characterize the dysarthria in
Huntington's disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
| Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
| Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
| Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
| Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
| Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
| Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
| Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
| Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
| Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
| Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
| Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
| Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
| Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
| Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
| Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
| Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A | |
| Recruiting |
NCT05243017 -
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
|
Phase 1/Phase 2 |